IL-FOURKITES
6.3.2023 09:01:40 CET | Business Wire | Press release
Leading real-time supply chain visibility company FourKites today announced it will bring its network of end-to-end, real-time supply chain data to Spotos’ European customers. German-based Spotos offers a digital freight forwarding platform that gives shippers access to a wide network of carriers across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005078/en/
FourKites and Spotos Join Forces to Bring Real-time Supply Chain Visibility to European Shippers (Graphic: Business Wire)
The partnership can give Spotos’ customers up-to-the-minute predictive estimated times of arrival (ETAs) and real-time status updates for their shipments at anytime, anywhere in Europe, whether in transit or at rest. With these advanced insights provided by FourKites, Spotos’ customers can reduce dwell and detention costs while optimising their network as shippers look to manage their costs better.
“Our mission is to revolutionise traditional freight exchange by enabling the best transparency, simplicity and accessibility for small and medium shippers,” said Šarūnas Stanislovėnas, founder and CEO of Spotos. “Now, thanks to FourKites' predictive insights, we will be able to provide our customers with ETAs that are more accurate and detailed than other available technologies could reliably deliver."
Spotos will also leverage FourKites’ carrier visibility platform, NIC-Place. This will give its customers access to granular data, including temperature tracking data for high-value transports, such as pharmaceuticals, fresh and frozen products, and electronic equipment throughout all parts of their fleet. With its proprietary Data Control Center (DCC), FourKites’ NIC-Place solution can provide a flexible and secure way for carriers to share supply chain data with customers, while giving them complete control of their business, their network and their data.
Based in Berlin, Spotos’ fully automated spot freight forwarding platform assures the highest-level service experience for small and medium-sized (SMB) shippers, regardless of their order volume or frequency. FourKites’ offering — powered by cutting-edge artificial intelligence and machine learning — will integrate with Spotos’ platform to extend visibility beyond transportation into yards, warehouses, stores and more.
Visibility across the entire supply chain network is crucial for SMB customers shipping high-value goods. By leveraging FourKites’ market-leading data network, Spotos’ customers can dynamically react to changes in plans and make more informed decisions in real time. In addition, FourKites will fuel insights that drive smarter operational planning and uncover new opportunities for operational efficiencies and cost savings.
“We’re delighted to team up with Spotos to ensure their customers can seamlessly track their freight in one unified platform,” said Marc Boileau, FourKites’ Senior Vice President of Sales, Network & Operations EMEA. “With FourKites, Spotos gets the most advanced tracking features for true end-to-end visibility, giving them a single pane of glass solution and the industry’s most accurate predictive ETAs for every shipment.”
“We’re excited about our partnership with FourKites,” continued Stanislovėnas. “FourKites has proven itself to be a true partner that has our best interests at heart and is always striving to do what’s right for our business and our customers.”
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
About Spotos
Spotos revolutionised the old-school logistics industry, combining it with cutting-edge innovation, customer-oriented design, and a futuristic vision. It offers shippers access to a wide network of carriers across the EU region. The platform powertrain includes data science, artificial intelligence and machine learning.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
